Micrographia Bio

Using machine learning to turn spatial proteomics into a drug discovery engine

First Investment: 2022

If it were possible to watch drugs molecules at work under a microscope — seeing precisely how they act on different proteins inside cells — it would revolutionize drug development. Micrographia is doing just that. The company uses machine learning to analyze microscopy images at high throughput, allowing researchers and drug developers to unravel disease mechanisms at the subcellular level.

Explore Companies

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery